Intensive Care Research Past Projects


A European observational study to gather information on the nature of traumatic brain injury across Europe and identify the most effective interventions.

This study was funded by the European Union and led by the University of Leiden.It was led by the University of Leiden and funded by the European Union in order
More information about this study can be found on the UK Clinical Trials website :



This national observational study aimed to define the pattern of multi-organ failure in trauma centres across the UK .Run by Queen Mary’s University London. To read more


Principal Investigator: Dr Matt Thomas
Investigators: Dr Chris Newell, Dr Keith Davies, Dr Aidan Marsh

This interventional trial compared different ways of using a ventilator (“breathing machine”) in severe lung injury. It was stopped early in October 2017 after publication of a similar study raised concerns about safety of the new approach. Results from this trial will be available in due course. The study was led by Monash University in Melbourne, Australia and the Australia and New Zealand Intensive Care Society (ANZICS).


Principal Investigator: Dr Matt Thomas
Investigators: Dr Adam Green, Dr Caroline Kane, Dr Victoria Male

This national multi-centre study is testing the performance of a new way of diagnosing septicaemia (“blood poisoning”).

Sepsis is the term used to describe serious infections. Up to half of all hospitalised patients with sepsis may die. It is caused by microrganisms (microbes), such as bacteria, and one of the most important parts of treating patients with sepsis is to give them the right antibiotics as soon as possible to treat the underlying infection. Many different microbes can cause sepsis. Currently the only way to find out for sure which one to target in any particular patient is to wait for it to grow in a laboratory from a sample of their blood, or other samples (culture).

As it takes at least 24-48 hours to grow in the laboratory, doctors choose 'best guess' antibiotics that can treat a lot of different microbes before they know which one would be the best fit. These are not always the right antibiotics for that particular individual, and sometimes patients only get the right treatment once there is a result from the laboratory.

Randox Ltd has recently developed a new bedside device based on technology that is able to identify bacteria in patients' blood within just one hour. Looking only for characteristic fragments of over 40 different microbes means that doctors’ decisions about which treatment to give patients will not need to wait for over a day for the microbe to grow in a laboratory. This will allow treatments to be better targeted from a much earlier stage. The aim of this study is to investigate how well the new TEST-IT is able to identify microbes in comparison to blood culture, which is currently the best method of measurement (gold standard).

Planned end date: February 2018
is run  by the Northern Ireland Clinical Trials Unit (NICTU) and is funded by Innovate UK.

65 Trial

Principal Investigators: Beverley Faulkner, Dr Matt Thomas
Investigator: Dr Katherine Fok

This national multi-centre study was run by the Intensive Care National Audit and Research Centre (ICNARC) and funded by the National Institute of Health Research (NIHR). It asked if reducing the dose of medication to support blood pressure (“vasopressors”) in shock in patients over 65 will produce a better outcome to standard practice